reports
Nutra Pharma Corp. Reaches Settlement with SEC
Nutra Pharma Corp. Reaches Settlement with SEC Nutra Pharma Corp. has reached a bifurcated settlement with the SEC along with its CEO and a Consultant to the company CORAL SPRINGS, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- (OTC: NPHC), (“Nutra Pharma” or the “Company”) reached a settlement with the U.S. Securities and Exchange Commission (“SEC”) earlier this week. On March 19, 2024, the United States District Court for the Eastern District of New York in SEC v. Nutra Pharma Corporation, Erik Deitsch a/k/a Rik Deitsch, and Sean Peter McManus, Case No. 1:18-cv-05459-JS (E.D.N.Y.), approv...
- GlobalData Department
Nutra Pharma Corp (NPHC) - Pharmaceuticals & Healthcare - Deals and Al...
Summary Nutra Pharma Corp (Nutra Pharma) acquires, licenses and commercializes pharmaceutical products, technologies, homeopathic drugs and ethical drugs for managing cancer, neurological disorders, autoimmune and infectious diseases, including human Immunodeficiency virus (HIV), multiple sclerosis (MS), adrenomyeloneuropathy (AMN) and pain. It also markets over-the-counter (OTC) pain management products under the brands Nyloxin and Pet Pain-Away. The company's wholly owned subsidiaries include...
- GlobalData Department
Nutra Pharma Corp (NPHC) - Medical Equipment - Deals and Alliances Pro...
Summary Nutra Pharma Corp (Nutra Pharma) acquires, licenses and commercializes pharmaceutical products, technologies, homeopathic drugs and ethical drugs for managing cancer, neurological disorders, autoimmune and infectious diseases, including human Immunodeficiency virus (HIV), multiple sclerosis (MS), adrenomyeloneuropathy (AMN) and pain. It also markets over-the-counter (OTC) pain management products under the brands Nyloxin and Pet Pain-Away. The company's wholly owned subsidiaries include...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.